Clinical burden and health service challenges of chronic heart failure

British Journal of General Practice

Volumn 60, Issue 577, 2010, Pages 611-615

  Hobbs, Richard ^a,b  

^a School of Health and Population Sciences   (United Kingdom)

^b UNIVERSITY OF BIRMINGHAM   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

BETA ADRENERGIC RECEPTOR BLOCKING AGENT; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR;

ARTICLE; DIAGNOSTIC ACCURACY; ELECTROCARDIOGRAM; HEALTH CARE COST; HEALTH CARE PERSONNEL; HEALTH CARE SYSTEM; HEALTH SERVICE; HEART FAILURE; HEART INFARCTION; HEART LEFT VENTRICLE FAILURE; HOSPITAL ADMISSION; INCIDENCE; MORBIDITY; MORTALITY; PREVALENCE; QUALITY OF LIFE;

ADRENERGIC BETA-ANTAGONISTS; AGED; AGED, 80 AND OVER; ANGIOTENSIN-CONVERTING ENZYME INHIBITORS; CHRONIC DISEASE; COST OF ILLNESS; FEMALE; HEALTH RESOURCES; HEALTH SERVICES ACCESSIBILITY; HEART FAILURE; HUMANS; MALE; MIDDLE AGED; QUALITY OF LIFE;

EID: 78650583387     PISSN: 09601643     EISSN: None     Source Type: Journal    
DOI: 10.3399/bjgp10X515133     Document Type: Article

References (65)

1. Gillum RF. Epidemiology of heart failure in the United States. Am Heart J 1993; 126(4): 1042-1047.
2. O'Connell JB, Bristow MR. Economic impact of heart failure in the United States: time for a different approach. J Heart Lung Transplant 1994; 13(Suppl 4): S107-S112.
3. The CONSENSUS Trial Study Group. Effects of enalapril on mortality in severe congestive heart failure. Results of the Cooperative North Scandinavian Enalapril Survival Study (CONSENSUS). The CONSENSUS Trial Study Group. N Engl J Med 1987; 316(23): 1429-1435.
4. Hobbs FDR, Roalfe AK, Davis RC, et al. Prognosis of all-cause heart failure and borderline left ventricular systolic dysfunction: 5 year mortality follow-up of the Echocardiographic Heart of England Screening Study (ECHOES). Eur Heart J 2007; 28(9): 1128-1134.
5. McKee PA, CastelliWP,McNamara PM, Kannell WB. The natural history of heart failure: The Framingham Study. N Engl J Med 1971; 285(26): 1441-1446.
6. Ho KKL, Pinsky JL, KannelWB. The epidemiology of heart failure: the Framingham study. J Am Cardiol 1993; 22(Suppl A): 6A-13A.
7. Marantz PR, Tobin JN,Wassertheil-Smoller S, et al. The relationship between left ventricular systolic function and congestive heart failure diagnosed by clinical criteria. Circulation 1988; 77(3): 607-612.
8. Clarke KW, Gray D, Hampton JR. How common is heart failure? Evidence from PACT (prescribing analysis and cost) data in Nottingham. J Public Health Med 1995; 17(4): 459-464.
9. Parameshwar J, Shackell MM, Richardson A, et al. Prevalence of heart failure in three general practices in NorthWest London. Br J Gen Pract 1992; 42(360): 287-289.
10. McDonagh TA,Morrison CE, Lawrence A, et al. Symptomatic and asymptomatic left ventricular systolic dysfunction in an urban population. Lancet 1997; 350(9081): 829-833.
11. Morgan S, Smith H, Simpson I, et al. Prevalence and clinical characteristics of left ventricular dysfunction among elderly patients in general practice setting: cross sectional survey. BMJ 1999; 318(7180): 368-372.
12. Poole-Wilson PA. History, definition, and classification of heart failure. In: Poole-Wilson PA, ColucciWS,Massie BM, et al (eds). Heart failure: scientific principles and clinical practice. Edinburgh: Churchill Livingston, 1997; 268-277.
13. Working Group Report. How to diagnose diastolic heart failure: European Study Group on Diastolic Heart Failure. Eur Heart J 1998; 19(7): 990-1003.
14. Davies MK, Hobbs FDR, Davis RC, et al. Prevalence of leftventricular systolic dysfunction and heart failure in the Echocardiographic Heart of England Screening study: a population based study. Lancet 2001; 358(9280): 439-445.
15. Cowie MR,Wood DA, Coats A, et al. Incidence and aetiology of heart failure: a population-based study. Eur Heart J 1999; 20(6): 421-428.
16. MERIT-HF Study Group. Effect of metoprolol CR/XL in chronic heart failure:Metoprolol CR/XL Randomised Intervention Trial in Congestive Heart Failure (MERIT-HF). Lancet 1999; 353(9169): 2001-2007.
17. Digitalis Investigation Group. The effect of digoxin on mortality and morbidity in patients with heart failure. N Engl J Med 1997; 336(8): 525-533.
18. RALES Investigators. Effectiveness of spironolactone added to an angiotensin-converting enzyme inhibitor and a loop diuretic for severe chronic congestive heart failure (the Randomized Aldactone Evaluation Study [RALES]). Am J Cardiol 1996; 78(8): 902-907.
19. Domanski MJ. Beta-Blocker Evaluation of Survival Trial (BEST). J Am Coll Cardiol 2000; 35(Suppl A): 202A.
20. Ho KKL, Anderson KM, KannelWB, et al. Survival after the onset of congestive heart failure in Framingham Heart Study Subjects. Circulation 1993; 88(1): 107-115. (Pubitemid 23195439)
21. Schocken DD, Arrieta MI, Leaverton PE, Ross EA. Prevalence and mortality rate of congestive heart failure in the United States. J Am Coll Cardiol 1992; 20(2): 301-306.
22. McDonagh TA, CunninghamAD,Morrison CE, et al. Left ventricular dysfunction, natriuretic peptides, and mortality in an urban popultion. Heart 2001; 86(1): 21-26.
23. Khand A, Gemmel I, Clark AL, Cleland JG. Is the prognosis of heart failure improving? J Am Coll Cardiol 2000; 36(7): 2284-2286.
24. Stewart S,MacIntyre K, Hole DJ, et al.More 'malignant' than cancer? Five-year survival following a first admission for heart failure. Eur J Heart Fail 2001; 3(3): 315-322.
25. Task Force for Diagnosis and Treatment of Acute and Chronic Heart Failure 2008 of European Society of Cardiology, Dickstein K, Cohen-Solal A, et al. ESC Guidelines for the diagnosis and treatment of acute and chronic heart failure 2008: the Task Force for the Diagnosis and Treatment of Acute and Chronic Heart Failure 2008 of the European Society of Cardiology. Developed in collaboration with the Heart Failure Association of the ESC (HFA) and endorsed by the European Society of Intensive Care Medicine (ESICM). Eur Heart J 2008; 29(19): 2388-2442.
26. Stewart AL, Greenfield S, Hays RD, et al. Functional status and wellbeing of patients with chronic conditions. Results from the medical outcomes study. JAMA 1989; 262(7): 907-913.
27. Cline CM,Willenheimer RB, Erhardt LR, et al. Health related quality of life in elderly patients with heart failure. Scand Cardiovasc J 1999; 33(5): 278-285. (Pubitemid 29465528)
28. Havranek EP,Ware MG, Lowes BD. Prevalence of depression in congestive heart failure. Am J Cardiol 1999; 84(3): 348-350.
29. Murberg TA, Bru E, Svebak S, et al. Depressed mood and subjective health symptoms as predictors of mortality in patients with congestive heart failure: a two-years follow-up study. Int J Psychiatry Med 1999; 29(3): 311-326.
30. Garg R, Yusuf S, for the Collaborative Group on ACE Inhibitor Trials. Overview of randomized trials of angiotensin-converting enzyme inhibitors on mortality and morbidity in patients with heart failure. JAMA 1995; 273(18): 1450-1456.
31. Lechat P, PackerM, Chalon S, et al. Clinical effects of beta-adrenergic blockade in chronic heart failure: a meta-analysis of double-blind, placebo-controlled, randomized trials. Circulation 1998; 98(12): 1184-1191.
32. SOLVD Investigators. Effect of enalapril on survival in patients with reduced left ventricular ejection fractions and congestive heart failure. N Engl J Med 1991; 325(5): 293-302.
33. SOLVD Investigators. Effect of enalapril on mortality and the development of heart failure in asymptomatic patients with reduced left ventricular ejection fractions. N Engl J Med 1992; 327(10): 685-691.
34. Willenheimer R, Erhardt L, Cline C, et al. Exercise training in heart failure improves quality of life and exercise capacity. Eur Heart J 1998; 19(5): 774-781.
35. Rich MW, BeckhamV,Wittenberg C, et al. A multidisciplinary intervention to prevent the readmission of elderly patients with congestive heart failure. N Engl J Med 1995; 333(18): 1190-1195.
36. Murray SA, Boyd K, Kendall M, et al. Dying of lung cancer or cardiac failure: prospective qualitative interview study of patients and their carers in the community. BMJ 2002; 325(7370): 929.
37. Cleland JG, Swedberg K, Follath F, et al. The EuroHeart Failure survey programme-a survey on the quality of care among patients with heart failure in Europe Part 1: patient characteristics and diagnosis. Eur Heart J 2003; 24(5): 442-463. (Pubitemid 36286187)
38. Sutton GC. Epidemiological aspects of heart failure. Am Heart J 1990; 120(6 Pt 2): 1538-1540.
39. McMurray J,McDonagh T,Morrison CE, Dargie HJ. Trends in hospitalisation for heart failure in Scotland 1980-1990. Eur Heart J 1993; 14(9): 1158-1162.
40. Eriksson H. Heart failure: a growing public health problem. J Intern Med 1995; 237(2): 135-141.
41. Bundkirchen A, Schwinger RHG. Epidemiology and economic burden of chronic heart failure. Eur Heart J 2004; 6(Suppl D): D57-D60.
42. Owan TE, Hodge DO, Herges RM, et al. Trends in prevalence and outcome of heart failure with preserved ejection fraction. N Engl J Med 2006; 355(3): 251-259.
43. Hunt SA, AbrahamWT, Chin MH, et al. ACC/AHA 2005 Guideline Update for the Diagnosis and Management of Chronic Heart Failure in the Adult: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines (Writing Committee to Update the 2001 Guidelines for the Evaluation and Management of Heart Failure): developed in collaboration with the American College of Chest Physicians and the International Society for Heart and Lung Transplantation: endorsed by the Heart Rhythm Society. Circulation 2005; 112(12): e154-e235.
44. Cleland JGF, Cohen-Solal A, Cosin Aguilar J, et al.Management of heart failure in primary care (the IMPROVEMENT of Heart Failure Programme): an international survey. Lancet 2003; 360(9346): 1631-1641.
45. Davie AP, Francis CM, Love MP, et al. Value of an electrocardiogram in identifying heart failure due to left ventricular systolic dysfunction. BMJ 1996; 312(7025): 222.
46. The NETWORK Investigators. Clinical outcome with enalapril in symptomatic chronic heart failure; a dose comparison. Eur Heart J 1998; 19(3): 481-489.
47. Badgett RG,Mulrow CD, Otto PM, Ramirez G. How well can the chest radiograph diagnose left ventricular dysfunction? J Gen Intern Med 1996; 11(10): 625-634.
48. Alam M, Rosenhamer G, Hogland C. Compatibility of echocardiography and chest x-ray following myocardial infarction. J Intern Med 1989; 226(3): 771-773.
49. Badgett RG, Lucey LR,Murlow CD. Can clinical examination diagnose left-sided heart failure in adults. JAMA 1997; 277(21): 1712-1719.
50. Weeldon NM,McDonald TM, Fluker CJ, et al. Echocardiography in chronic heart failure in the community. Q J Med 1993; 86(1): 17-20.
51. Hobbs FDR, Davis RC,McLeod S, et al. Prevalence of heart failure in 'high risk' groups. J Am Coll Cardiol 1998; 31(S5): 85C.
52. Remes J,Miettinen H, Reunanen A, Pyorala K.Validity of clinical diagnosis of heart failure in primary health care. Eur Heart J 1991; 12(3): 315-321.
53. Anonymous. Failure to treat heart failure [editorial]. Lancet 1992; 339: 278-279.
54. Clarke KW, Gray D, Hampton JR. Evidence of inadequate investigation and treatment of patients with heart failure. Br Heart J 1994; 72(6): 584-587. (Pubitemid 24224829)
55. Hobbs FDR, Davis RC, Roalfe AK, et al. Reliability of N-terminal pro-brain natriuretic peptide assay in diagnosis of heart failure: cohort study in representative and high risk community populations. BMJ 2002; 324(7352): 1498-1502.
56. Hobbs FDR, Roalfe AK, Davis RC, et al. Reliability of N-terminal proBNP (NT-proBNP) assay in diagnosing left ventricular systolic dysfunction within representative and high-risk populations. Heart 2004; 90(8): 866-870.
57. Troughton R, Frampton C, Yandle T, et al. Treatment of heart failure guided by plasma aminoterminal brain natriuretic peptide (N-BNP) concentrations. Lancet 2000; 355(9210): 1126-1130.
58. Pfeffer MA, Braunwald E,Moye LA, et al. Effect of captopril on mortality and morbidity in patients with left ventricular dysfunction after myocardial infarction. Results of the survival and ventricular enlargement trial. The SAVE Investigators. N Engl J Med 1992; 327(10): 669-677.
59. CIBIS-II Investigators and Committees. The Cardiac Insufficiency Bisoprolol Study II. Lancet 1999; 353(9146): 9-13.
60. American College of Cardiology/American Heart Association. Guidelines for the evaluation and management of heart failure. Report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines (Committee on Evaluation and Management of Heart failure). Circulation 1995; 92(9): 2764-2727.
61. Pitt B,White H, Nicolau J, et al; EPHESUS Investigators. Eplerenone reduces mortality 30 days after randomization following acute myocardial infarction in patients with left ventricular systolic dysfunction and heart failure. J Am Coll Cardiol 2005; 46(3): 425-431. (Pubitemid 41040281)
62. Juurlink DN,Mamdani MM, Lee DS, et al. Rates of hyperkalemia after publication of the Randomized Aldactone Evaluation Study. N Engl J Med 2004; 351(6): 543-551.
63. Pfeffer MA, Swedberg K, Granger CB, et al. Effects of candesartan on mortality and morbidity in patients with chronic heart failure: the CHARM-Overall programme. Lancet 2003; 326(9386): 759-766. (Pubitemid 37093915)
64. Clarke KW, Gray D, Hampton JR. Evidence of inadequate investigation and treatment of patients with heart failure. Br Heart J 1994; 71(6): 584-587.
65. Hobbs FDR, Jones MI, Allan TS, et al. European survey of primary care physician perceptions and practice in heart failure diagnosis and management( Euro-HF study). Eur Heart J 2000; 21(22): 1877-1887.